As a rapidly expanding drug modality, antibody drugs against RTKs have been actively investigated for the treatment of SCLC, and insulin-like growth factor receptor (IGF-1R) is one of such potential RTK targets [3–7]. This evidence concerns the gene IGF1R and small cell lung carcinoma.